文献速递神经肌肉病

肌萎缩侧索硬化患者预后:个体化预测模型的开发与验证

Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.
PubMed 文献 · Lancet Neurol · 2018-03-26

该研究基于欧洲14个ALS中心的患者数据,开发并外部验证了一个预测ALS患者复合生存结局的多变量模型。模型纳入8个预测因子,外部预测准确性的c统计量为0.78,校准斜率为1.01,并据此定义了五组中位预测与观察生存时间不同的患者群体。

要点

  • 模型纳入球部起病、发病年龄、诊断确定性、诊断延迟、用力肺活量、进展速度、额颞叶痴呆和C9orf72重复扩增8个预测因子。
  • 外部预测准确性c统计量为0.78(95%CI 0.77-0.80),校准斜率为1.01(95%CI 0.95-1.07)。
  • 模型定义五组患者,中位预测与观察生存时间从极短组17.7个月与16.5个月到极长组91.0个月与85.6个月。

核心结论

  • 研究开发了一个经外部验证的模型,用于预测欧洲ALS患者至无创通气每日超过23小时、气管造口或死亡的复合生存结局。
  • 该模型可用于个体化患者管理、咨询和未来试验设计,但仅限医生使用以最大化获益并防止伤害。

研究设计与样本

  • 从比利时、法国、荷兰、德国、爱尔兰、意大利、葡萄牙、瑞士和英国的14个专门ALS中心获取患者数据,每个中心指定为一个队列。
  • 所有患者均在中心排除其他诊断后确诊,并按修订版El Escorial标准分类。
  • 评估16个患者特征作为复合生存结局的潜在预测因子,在最大人群数据集中采用后向消除法结合自举法进行预测因子选择。
  • 在超过70%的自举重采样中选中的预测因子用于开发多变量Royston-Parmar模型。
  • 通过内部-外部交叉验证评估模型在外部人群中的预测准确性异质性,使用一致性(c)统计量量化区分度,校准斜率评估校准度。

主要发现

  • 八个候选预测因子进入预测模型:球部起病对比非球部起病(单变量风险比[HR] 1.71,95%CI 1.63-1.79),发病年龄(1.03,1.03-1.03),确诊ALS对比很可能或可能ALS(1.47,1.39-1.55),诊断延迟(0.52,0.51-0.53),用力肺活量(HR 0.99,0.99-0.99),进展速度(6.33,5.92-6.76),额颞叶痴呆(1.34,1.20-1.50),以及C9orf72重复扩增存在(1.45,1.31-1.61),所有p<0.0001。
  • 模型外部预测准确性的c统计量为0.78(95%CI 0.77-0.80;95%预测区间[PI] 0.74-0.82),校准斜率为1.01(95%CI 0.95-1.07;95% PI 0.83-1.18)。
  • 模型定义五组具有不同中位预测(SE)和观察(SE)症状发作至复合生存结局时间(月)的患者:极短组17.7(0.20)、16.5(0.23);短组25.3(0.06)、25.2(0.35);中间组32.2(0.09)、32.8(0.46);长组43.7(0.21)、44.6(0.74);极长组91.0(1.84)、85.6(1.96)。

关键数值与推荐

  • 预测因子选择标准为在超过70%的自举重采样中选中。
  • 复合生存结局定义为症状发作至无创通气每日超过23小时、气管造口或死亡的时间。
  • 模型区分度以c统计量评估,校准度以校准斜率评估。

临床怎么用

  • 作者认为该模型可用于个体化患者管理、咨询和未来试验设计。
  • 作者指出为最大化获益并防止伤害,该模型仅限医生使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive, fatal motor neuron disease with a variable natural history. There are no accurate models that predict the disease course and outcomes, which complicates risk assessment and counselling for individual patients, stratification of patients for trials, and timing of interventions. We therefore aimed to develop and validate a model for predicting a composite survival endpoint for individual patients with ALS. METHODS: We obtained data for patients from 14 specialised ALS centres (each one designated as a cohort) in Belgium, France, the Netherlands, Germany, Ireland, Italy, Portugal, Switzerland, and the UK. All patients were diagnosed in the centres after excluding other diagnoses and classified according to revised El Escorial criteria. We assessed 16 patient characteristics as potential predictors of a composite survival outcome (time between onset of symptoms and non-invasive ventilation for more than 23 h per day, tracheostomy, or death) and applied backward elimination with bootstrapping in the largest population-based dataset for predictor selection. Data were gathered on the day of diagnosis or as soon as possible thereafter. Predictors that were selected in more than 70% of the bootstrap resamples were used to develop a multivariable Royston-Parmar model for predicting the composite survival outcome in individual patients. We assessed the generalisability of the model by estimating heterogeneity of predictive accuracy across external populations (ie, populations not used to develop the model) using internal-external cross-validation, and quantified the discrimination using the concordance (c) statistic (area under the receiver operator characteristic curve) and calibration using a calibration slope. FINDINGS: Data were collected between Jan 1, 1992, and Sept 22, 2016 (the largest data-set included data from 1936 patients). The median follow-up time was 97·5 months (IQR 52·9-168·5). Eight candidate predictors entered the prediction model: bulbar versus non-bulbar onset (univariable hazard ratio [HR] 1·71, 95% CI 1·63-1·79), age at onset (1·03, 1·03-1·03), definite versus probable or possible ALS (1·47, 1·39-1·55), diagnostic delay (0·52, 0·51-0·53), forced vital capacity (HR 0·99, 0·99-0·99), progression rate (6·33, 5·92-6·76), frontotemporal dementia (1·34, 1·20-1·50), and presence of a C9orf72 repeat expansion (1·45, 1·31-1·61), all p<0·0001. The c statistic for external predictive accuracy of the model was 0·78 (95% CI 0·77-0·80; 95% prediction interval [PI] 0·74-0·82) and the calibration slope was 1·01 (95% CI 0·95-1·07; 95% PI 0·83-1·18). The model was used to define five groups with distinct median predicted (SE) and observed (SE) times in months from symptom onset to the composite survival outcome: very short 17·7 (0·20), 16·5 (0·23); short 25·3 (0·06), 25·2 (0·35); intermediate 32·2 (0·09), 32·8 (0·46); long 43·7 (0·21), 44·6 (0·74); and very long 91·0 (1·84), 85·6 (1·96). INTERPRETATION: We have developed an externally validated model to predict survival without tracheostomy and non-invasive ventilation for more than 23 h per day in European patients with ALS. This model could be applied to individualised patient management, counselling, and future trial design, but to maximise the benefit and prevent harm it is intended to be used by medical doctors only. FUNDING: Netherlands ALS Foundation.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018. PMID: 29598923. doi:10.1016/S1474-4422(18)30089-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。